A drug that targets multiple pathogenic steps in diabetic retinopathy may be an ideal therapeutic strategy for the disease, Vanderbilt researchers report.

Poorly functioning AMPARs have been linked to a wide range of neurological and psychiatric disorders including seizures, Alzheimer’s disease, major depression and autism spectrum disorder. Understanding how AMPARs are formed and operate is essential for the rational design of pharmacological compounds that, by tuning AMPAR activity up or down, could improve treatment of these conditions.

A team of researchers has received a $1 million grant from the W.M. Keck Foundation to explore a novel model of atherosclerosis development.

Jane Park, PhD, an active member of the Vanderbilt University faculty for 60 years and widow of pioneering diabetes researcher Charles Rawlinson “Rollo” Park, MD, died Aug. 19 in Nashville. She was 94.

Meena Madhur, MD, PhD, has received a Presidential Early Career Award for Scientists and Engineers.

P-glycoprotein distinguishes between chemicals that it will expel from a cell and inhibitors that block its action.

A new program at Vanderbilt will help researchers determine more precisely how genetic variations contribute to disease and what potentially can be done to put them right.